Table 3

Incidence of the most common (≥5%) AEs by treatment cycle (SES)

Treatment cycle
AE, n (%)1 (n=76)2 (n=72)3 (n=68)4 (n=66)5 (n=64)
Patients with ≥1 AE53 (70)50 (66)50 (66)36 (47)35 (46)
Dysphagia*14 (18)10 (14)11 (16)7 (11)10 (16)
Nasopharyngitis10 (13)11 (15)11 (16)11 (17)8 (13)
Headache8 (11)16 (22)9 (13)6 (9)8 (13)
Neck pain6 (8)5 (7)6 (9)3 (5)5 (8)
Dry mouth4 (5)3 (4)4 (6)1 (2)1 (2)
Back pain3 (4)3 (4)4 (6)1 (2)0 (0)
Diarrhoea1 (1)0 (0)5 (7)0 (0)2 (3)
  • *Patients were directly questioned about swallowing difficulties and evaluated for dysphagia using a 5–point dysphagia scale adapted from Comella et al20 at all visits and through telephone interviews.

  • AE, adverse event; SES, safety evaluation set.